Home

Passage Bio, Inc. (PASG)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Passage Bio, Inc. (PASG)

Go deeper and ask any question about PASG

Company Performance

Current Price

as of Sep 13, 2024

$0.81

P/E Ratio

N/A

Market Cap

$49.83M

Description

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Metrics

Overview

  • HQPhiladelphia, PA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerPASG
  • Price$0.8067+8.12%

Trading Information

  • Market Cap$49.83M
  • Float79.07%
  • Average Daily Volume (1m)246,095
  • Average Daily Volume (3m)246,477
  • EPS-$1.36

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$15.99M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$16.14M
  • EV-$16.63M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
Documents